Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications.

@article{MosesKolko2005NeonatalSA,
  title={Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications.},
  author={Eydie L. Moses-Kolko and Debra L Bogen and James M. Perel and Amy Bregar and Kathleen Uhl and Bob Levin and Katherine L. Wisner},
  journal={JAMA},
  year={2005},
  volume={293 19},
  pages={
          2372-83
        }
}
CONTEXT A neonatal behavioral syndrome linked to in utero serotonin reuptake inhibitor (SRI) exposure during the last trimester of pregnancy has been identified. The US Food and Drug Administration (FDA) and drug manufacturers have recently agreed to a class labeling change for SRIs, which include selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs), to include information about potential adverse events in neonates exposed in utero… 
In Utero Exposure to Selective Serotonin Reuptake Inhibitors: Evidence for Poor Neonatal Adaptation
TLDR
This article will critically evaluate the literature regarding perinatal outcomes for infants exposed to SSRI/SNRIs in utero, suggesting practice implications for nursing, medical care, and family education and support for those exposed.
Serotonin Reuptake Inhibitor-Induced Perinatal Complications
  • S. Gentile
  • Medicine, Psychology
    Paediatric drugs
  • 2007
TLDR
The opportunity of tapering and discontinuing SRIs in late pregnancy should be taken into consideration, although to date the evidence to support such a clinical decision is preliminary.
Neonatal Withdrawal Syndrome following Late in utero Exposure to Selective Serotonin Reuptake Inhibitors: A Systematic Review and Meta-Analysis of Observational Studies
TLDR
The present work provides a framework for the identification of neonatal SSRI withdrawal syndrome and suggests tapering and discontinuation of antidepressant drugs before and during the early phase of pregnancy are worth attempting to prevent the occurrence of this syndrome.
Short-Term Neonatal Outcome among Term Infants after in utero Exposure to Serotonin Reuptake Inhibitors
TLDR
Despite the high incidence of clinical signs among infants born to SRI-treated mothers, most of their symptoms were mild and self-limited, and postnatal monitoring and observation is needed.
Do Maternal Pharmacogenetics Impact the Neonatal Abstinence Syndrome Following In Utero Exposure to Antidepressant Medications?
Selective serotonin reuptake inhibitors in pregnancy and infant outcomes.
TLDR
Information is provided that should be used to make individual risk-benefit decisions when considering the treatment of depression during pregnancy, including whether or not to prescribe an SSRI.
Fetal Effects of In Utero Serotonin Reuptake Inhibitor (SRI) Antidepressant Exposure
TLDR
Given the paucity of empiric fetal data in humans, what is known about three postnatal findings that may reflect fetal developmental sequelae associated with in utero SRI exposure are drawn.
Prenatal Exposure to Selective Serotonin Reuptake Inhibitors and Infant Outcome
  • H. Malm
  • Medicine
    Therapeutic drug monitoring
  • 2012
TLDR
Causality cannot be confirmed in observational study settings, however, parallel results in individual studies regarding the cardiac malformations and pulmonary hypertension of the newborn, together with an existing biologically plausible mechanism behind these events may support causality.
Neonatal Discontinuation Syndrome in Serotonergic Antidepressant-Exposed Neonates.
TLDR
The presence of neonatal signs at 2-4 weeks was more closely associated with prematurity than with in utero SRI or mood disorder exposure, and a significant relationship between Finnegan signs and preterm birth.
Early Morbidity and Mortality Following In Utero Exposure to Selective Serotonin Reuptake Inhibitors
TLDR
The children in the SSRI group were more likely to be admitted to hospital in the first years of life, and this may reflect their prenatal exposure to SSRIs, be related to maternal depression, or SSRI use may be a proxy for an environmental exposure such as smoking, or a combination of these factors.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 58 REFERENCES
Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors
TLDR
Five cases of neonatal withdrawal syndrome after third trimester in utero SSRI exposure are reported, with Symptoms were irritability, constant crying, shivering, increased tonus, eating and sleeping difficulties and convulsions.
Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations.
TLDR
Infants exposed to SSRIs during late pregnancy are at increased risk for serotonergic central nervous system adverse effects, and the severity of these symptoms is significantly related to cord blood 5-HIAA levels.
Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure.
TLDR
While transient neonatal symptoms were found in infants after single-agent prenatal exposure to SSRIs, the addition of clonazepam appeared to alter paroxetine metabolism, leading to increased drug levels and risk for transient Neonatal symptoms.
Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study.
TLDR
The new SSRIs, fluvoxamine, paroxetine, and sertraline, do not appear to increase the teratogenic risk when used in their recommended doses.
Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior.
TLDR
Results provide the first systematic evidence that women who use SSRIs during pregnancy have healthy, full-birth-weight newborn infants who show disruptions in a wide range of neurobehavioral outcomes.
Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines.
TLDR
Exposure to certain psychotropic drugs in utero may increase the risk for some specific congenital anomalies, but the rate of occurrence of these anomalies even with the increased risk remains low.
Prolonged Prenatal Psychotropic Medication Exposure Alters Neonatal Acute Pain Response
TLDR
Prolonged prenatal SSRI exposure appears to be associated with reduced behavioral pain responses and increased parasympathetic cardiac modulation in recovery following an acute neonatal noxious event.
Perinatal outcome following third trimester exposure to paroxetine.
TLDR
When used near term, paroxetine is associated with a high rate of neonatal complications, possibly caused by its common discontinuation syndrome.
Effects of third trimester fluoxetine exposure on the newborn.
  • D. Goldstein
  • Medicine, Psychology
    Journal of clinical psychopharmacology
  • 1995
TLDR
It is unlikely that maternal fluoxetine use during the third trimester results in significant postnatal complications, and reported rates from the National Hospital Discharge Survey are likely to be low.
...
1
2
3
4
5
...